• SPX
  • $5,709.54
  • 0.01 %
  • $0.79
  • DJI
  • $42,196.52
  • 0.09 %
  • $39.55
  • N225
  • $38,552.06
  • 1.97 %
  • $743.30
  • FTSE
  • $8,316.94
  • 0.31 %
  • $26.08
  • IXIC
  • $17,925.12
  • 0.08 %
  • $14.76
Caribou Biosciences, Inc. (CRBU) Stock Price, News & Analysis

Caribou Biosciences, Inc. (CRBU) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.78

-$0.05

(-2.73%)

Day's range
$1.76
Day's range
$1.87
50-day range
$1.63
Day's range
$2.58
  • Country: US
  • ISIN: US1420381089
52 wk range
$1.5
Day's range
$8.33
  • CEO: Dr. Rachel E. Haurwitz Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.29
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (CRBU)
  • Company Caribou Biosciences, Inc.
  • Price $1.78
  • Changes Percentage (-2.73%)
  • Change -$0.05
  • Day Low $1.76
  • Day High $1.87
  • Year High $8.33

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $3.00
  • High Stock Price Target $3.00
  • Low Stock Price Target $3.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.38
  • Trailing P/E Ratio -1.41
  • Forward P/E Ratio -1.41
  • P/E Growth -1.41
  • Net Income $-102,070,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.